Halozyme Wins Injunction Blocking Merck's Keytruda SC in Europe
HALO sits 80% above its 52-week low of $61.225.
Summary
Halozyme secured an injunction halting manufacture and sale of Merck's Keytruda SC in multiple European markets. This is a major legal victory protecting Halozyme's ENHANZE technology and royalty stream. The ruling directly impacts Merck's subcutaneous Keytruda launch in Europe, a key competitive threat. Halozyme's Q2 royalty revenue was $308M, driven by ENHANZE partners; this injunction removes near-term uncertainty. The decision follows the recent argenx collaboration expansion and $1.5B convertible notes offering, strengthening Halozyme's IP position.
At the time of this announcement, HALO was trading at $110.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.5B. The 52-week trading range was $61.23 to $116.85. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: PR Newswire.